Nephrology

For patients with type 2 diabetes, a condition called non-alcoholic fatty liver disease (NAFLD) may be an important risk factor for diabetes-related chronic kidney disease (CKD), according to a study.

For patients with type 1 diabetes and end-stage renal disease (ESRD), simultaneous kidney-pancreas transplantation increases the chances of long-term survival compared to kidney transplantation alone.

For patients with type 1 diabetes, increased levels of uric acid in the blood may be an early sign of diabetic kidney disease–appearing before any significant change in urine albumin level, the standard screening test.

For critically ill patients, intensive insulin therapy (IIT) to keep blood sugar (glucose) at normal levels reduces the risk of acute kidney injury, reports a new study.

A new study confirms that chronic kidney disease (CKD) increases the already-high risk of serious cardiovascular events in diabetic patients with damage to the large blood vessels and suggests that treatment with the anti-diabetic drug pioglitazone may help to lower this risk.

Hemoglobin variability over time in dialysis patients proved a strong predictor of death from any cause, according to a new study.

Pioglitazone (Actos) appeared, at worst, neutral for cardiovascular risk, except heart failure, in yet another meta-analysis examining thiazolidinedione safety.

Although estimates have been adjusted downward in light of the most recent data, researchers still predict sharp increases in the U.S. incidence and prevalence of end-stage renal disease (ESRD) in the years ahead, according to a paper presented at the American Society of Nephrology’s 40th Annual Meeting and Scientific Exposition..

Creatinine screening needed in addition to albuminuria testing.

A type 2 diabetes drug taken orally and in widespread use for more than a decade has been found to have distinct advantages over nine other, mostly newer medications used to control the chronic disease, according to a study by researchers at Johns Hopkins.